Bundibugyo Ebola Surpasses 1,100 Cases, CDC Expands Response

The Centers for Disease Control and Prevention (CDC) is expanding its international and domestic response to an Ebola outbreak caused by Bundibugyo virus that has spread across the Democratic Republic of the Congo (DRC) and Uganda, becoming the largest recorded outbreak linked to this Ebola species.

As of June 25, 2026, health authorities have reported 1,139 confirmed cases and 293 confirmed deaths across affected countries, according to data published by the CDC and national ministries of health.

The outbreak has become a priority for public health agencies because of its scale, transmission dynamics, and the absence of an approved vaccine for Bundibugyo virus.

While the CDC assesses the risk to the US public as low, the agency has implemented travel-related measures and enhanced screening protocols to reduce the likelihood of imported cases.

Beyond Africa, the Pan American Health Organization (PAHO) has activated its Incident Management System to coordinate preparedness efforts across the Americas.

The PAHO is also preparing shipments of materials and reagents for molecular detection of Bundibugyo ebolavirus in selected countries with appropriate biosafety capabilities, based on regional risk assessments.

Bundibugyo Ebola Expansion Frame

According to the CDC, the DRC has confirmed 1,118 cases and 291 deaths as of June 23, making the event the country's 17th recorded Ebola outbreak and the second-largest Ebola outbreak on record. Uganda has reported 20 confirmed cases and two deaths as of June 25, while France has confirmed one imported case with no fatalities.

The outbreak emerged in early May when a hospital in the Bunia Health Zone, located in northeastern DRC, identified a cluster of severe illnesses among healthcare workers. Initial laboratory analyses conducted in the DRC did not confirm Ebola infection. However, subsequent testing found that eight of 13 samples were positive for an orthoebolavirus, while five samples produced inconclusive results.

Genetic sequencing later identified Bundibugyo virus as the cause of the outbreak. Bundibugyo virus is one of four orthoebolaviruses known to cause Ebola disease in humans. Patients have reported symptoms including fever, headache, vomiting, severe weakness, abdominal pain, nosebleeds, and hematemesis.

The current outbreak represents the third documented outbreak caused by Bundibugyo virus. Previous outbreaks occurred in Uganda in 2007 and in the DRC in 2012. According to historical data cited by the CDC, those outbreaks recorded case fatality rates of 32% and 55%, respectively.

Cases Rising, There Is Still No Vaccine

Unlike outbreaks caused by Zaire ebolavirus, for which vaccines and therapeutic options have become available in recent years, there is currently no licensed vaccine for Bundibugyo virus. Clinical management remains centered on supportive care, including hydration, symptom management, and treatment of secondary complications.

According to the CDC, the absence of a vaccine increases the importance of surveillance, case identification, isolation protocols, contact tracing, and healthcare worker protection. These measures have become central components of the response strategy being coordinated by national health authorities and international organizations.

The outbreak is also drawing attention because of the pace at which cases have accumulated. According to the CDC, the number of infections has increased faster than in any previous Ebola outbreak. The agency notes that epidemiological investigations remain ongoing and that case counts may continue to change as additional suspected infections are reviewed and standardized across reporting systems.

CDC Takes Some Measures

To support preparedness efforts, the CDC has conducted modeling exercises that evaluate a range of outbreak scenarios over the coming months. The agency states that these projections are intended to help public health authorities understand how intervention strategies may influence future case counts and mortality outcomes.

The modeling suggests that immediate and sustained public health support will be necessary to contain transmission in affected regions. While the CDC has not publicly disclosed specific projections, the agency indicates that stronger intervention measures are associated with more favorable outcomes.

The international response has expanded beyond Africa as governments seek to prevent cross-border transmission. The CDC has issued Travel Health Notices for both the DRC and Uganda and recommends avoiding non-essential travel to Ituri, Nord-Kivu, and Sud-Kivu provinces in the DRC.

Travelers entering affected areas are advised to take precautions to avoid exposure to infected individuals and to monitor symptoms for 21 days after departing the region. Ebola virus disease has an incubation period that can extend up to three weeks, making post-travel monitoring a key component of containment efforts.

Although South Sudan has not reported any confirmed Ebola cases associated with the outbreak, the country has been included in precautionary measures because of its shared borders with affected nations.

For healthcare systems, logistics providers, travel operators, emergency preparedness organizations, and companies with personnel operating in East and Central Africa, the outbreak highlights the operational importance of disease surveillance and business continuity planning.

Mexico's Preparedness Capacity Faces New Scrutiny

Whether Mexico qualifies for that first tier is a question the country's health authorities have not answered publicly.

While the country has announced more than MX$21 billion (US$1.2 billion) in pharmaceutical investment commitments under Plan Mexico during the last 18 months, including projects related to mRNA technologies, plasma fractionation, injectable manufacturing, and clinical research, efforts to strengthen epidemiological surveillance and diagnostic infrastructure remain ongoing.

In addition to these efforts, the Pandemic Fund recently approved Mexico's preparedness strategy, which includes investments to modernize information systems, expand the national laboratory network, and strengthen diagnostic capabilities, particularly in border regions.

But the discussion extends beyond pharmaceutical production capacity. According to Mexico's National Epidemiological Surveillance System, 142 diseases are currently monitored through national reporting mechanisms. Public health specialists note that outbreaks such as Bundibugyo Ebola underscore the importance of rapid molecular detection capabilities, biosafety protocols, and trained response personnel, particularly for pathogens for which no approved vaccine currently exists.

On June 1, the Coalition for Epidemic Preparedness Innovations announced funding for three Bundibugyo vaccine candidates being developed by IAVI, Moderna, and the University of Oxford, although those programs are not expected to influence the trajectory of the current outbreak.

While Mexico has proven its ability to secure large-scale pharmaceutical investments, the Ebola Bundibugyo outbreak poses a more difficult question. It challenges whether the nation's strategic goals encompass the less visible and commercially complex task of achieving epidemiological sovereignty.